Literature DB >> 20634098

Low potassium dextran is superior to University of Wisconsin solution in high-risk lung transplant recipients.

George J Arnaoutakis1, Jeremiah G Allen, Christian A Merlo, William A Baumgartner, John V Conte, Ashish S Shah.   

Abstract

BACKGROUND: The ideal solution for recovery of donor lungs remains unknown. Low potassium dextran (LPD) solution is most common, but University of Wisconsin (UW) solution is also used. The United Network for Organ Sharing (UNOS) database allows assessment of preservation solutions in a large cohort of lung transplant (LTx) patients.
METHODS: We retrospectively reviewed the UNOS data set for adult primary LTx patients (2005-2008) whose donor lungs were recovered with UW or LPD solution. Patients were stratified by UW vs LPD, and secondarily grouped by quartiles of the lung allocation score (LAS) to examine high-risk recipients. Kaplan-Meier (KM) short-term mortality (30 days, 90 days, 1 year) and rejection in the first year were examined for intervals with adequate follow-up. Cox proportional hazard regression using 11 variables examined all cause 1-year mortality.
RESULTS: Of 4,455 patients, 4,161 (93.4%) received LPD lungs and 294 (6.6%) received UW lungs, and 1,105 patients (24.8%) died during the study. There was no mortality difference based on flush solution with all patients examined together. However, patients in the upper 2 LAS quartiles (Q3: 37.8-45.4, Q4: > 45.4) receiving LPD lungs had greater 1-year survival of 81.5% vs 73.5% (p = 0.02). On multivariable analysis, flush with UW solution resulted in an increased risk of 1-year mortality (hazard ratio, 1.77. 95% confidence interval, 1.21-2.58; p = 0.003) vs LPD. Preservation solution did not affect rejection rates in the year after LTx. KM modeling demonstrated the effect of flush solution on survival (p = 0.02).
CONCLUSIONS: This study is the largest modern cohort to evaluate the effect of donor lung flush solutions on survival in adult LTx. UW solution increases the risk of 1-year mortality in high-risk LTx recipients.
Copyright © 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634098      PMCID: PMC3132206          DOI: 10.1016/j.healun.2010.05.031

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  25 in total

1.  Low-potassium dextran preservation solution improves lung function after human lung transplantation.

Authors:  S Fischer; A Matte-Martyn; M De Perrot; T K Waddell; Y Sekine; M Hutcheon; S Keshavjee
Journal:  J Thorac Cardiovasc Surg       Date:  2001-03       Impact factor: 5.209

2.  Low-potassium UW solution for lung preservation. Comparison with regular UW, LPD, and Euro-Collins solutions.

Authors:  T Oka; J D Puskas; E Mayer; P F Cardoso; S Q Shi; W Wisser; A S Slutsky; G A Patterson
Journal:  Transplantation       Date:  1991-12       Impact factor: 4.939

Review 3.  Thoracic organs: current preservation technology and future prospects; part 1: lung.

Authors:  Dirk Van Raemdonck
Journal:  Curr Opin Organ Transplant       Date:  2010-04       Impact factor: 2.640

4.  Flush perfusion with low potassium dextran solution improves early graft function in clinical lung transplantation.

Authors:  M Strüber; M Wilhelmi; W Harringer; J Niedermeyer; M Anssar; A Künsebeck; J D Schmitto; A Haverich
Journal:  Eur J Cardiothorac Surg       Date:  2001-02       Impact factor: 4.191

5.  Lung procurement by low-potassium dextran and the effect on preservation injury. Munich Lung Transplant Group.

Authors:  C Müller; H Fürst; H Reichenspurner; J Briegel; J Groh; B Reichart
Journal:  Transplantation       Date:  1999-10-27       Impact factor: 4.939

6.  Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.

Authors:  R C King; O A Binns; F Rodriguez; R C Kanithanon; T M Daniel; W D Spotnitz; C G Tribble; I L Kron
Journal:  Ann Thorac Surg       Date:  2000-06       Impact factor: 4.330

7.  Perfadex for clinical lung procurement: is it an advance?

Authors:  Tarek M Aziz; Thaseegaran M Pillay; Paul A Corris; Jonathan Forty; Colin J Hilton; Asif Hasan; John H Dark
Journal:  Ann Thorac Surg       Date:  2003-03       Impact factor: 4.330

8.  Clinical risk factors for primary graft failure following lung transplantation.

Authors:  Jason D Christie; Robert M Kotloff; Alberto Pochettino; Selim M Arcasoy; Bruce R Rosengard; J Richard Landis; Stephen E Kimmel
Journal:  Chest       Date:  2003-10       Impact factor: 9.410

9.  Influence of preservation solution on early lung function (Euro-Collins vs Perfadex).

Authors:  J M Rabanal; A M Ibañez; R Mons; A M Gonzalez; M Carbajo; J Ortega; F Zurbano
Journal:  Transplant Proc       Date:  2003-08       Impact factor: 1.066

10.  Low potassium dextran lung preservation solution reduces reactive oxygen species production.

Authors:  Rosemary F Kelly; Jozef Murar; Zhigang Hong; Daniel P Nelson; Fangxiao Hong; Anthony Varghese; E Kenneth Weir
Journal:  Ann Thorac Surg       Date:  2003-06       Impact factor: 4.330

View more
  3 in total

Review 1.  Preservation solutions for cardiac and pulmonary donor grafts: a review of the current literature.

Authors:  Nicholas Latchana; Joshua R Peck; Bryan Whitson; Sylvester M Black
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

Review 2.  Procurement of lungs from brain-dead donors.

Authors:  Prasad Krishnan; Sahar-Al-Sadat Sahar Saddoughi
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-03-19

3.  A physiologic and biochemical profile of clinically rejected lungs on a normothermic ex vivo lung perfusion platform.

Authors:  Timothy J George; George J Arnaoutakis; Claude A Beaty; Simran K Jandu; Lakshmi Santhanam; Dan E Berkowitz; Ashish S Shah
Journal:  J Surg Res       Date:  2012-11-27       Impact factor: 2.192

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.